ArticleACS omega2026
Continuous Monophasic Production of Pharmaceutical-Grade 5‑Hydroxymethylfurfural from Sugar Syrup.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A continuous-flow, monophasic catalytic process for the direct production of 5-hydroxymethylfurfural (5-HMF) from sugarcane syrup was developed using a microreactor platform to enable sustainable, pharmaceutical-compatible manufacturing. In contrast to conventional mineral-acid or biphasic systems, green citric acid was employed as a sustainable catalytic alternative. Low-toxicity solventsdeionized water, acetone, n-propanol, and isopropanolwere systematically evaluated to balance reaction performance and downstream compatibility. The results were benchmarked against a conventional solvent system. Key process parameters, including reaction temperature, residence time, catalyst loading, organic-to-aqueous (O:A) ratio, initial syrup concentration, and salt addition, were investigated and optimized using response surface methodology. Under the optimized conditions (15 wt % citric acid, 170 °C, O:A ratio of 0.25:1, and a residence time of 80 min), a maximum 5-HMF selectivity of 43.9% was achieved in a monophasic acetone-based system. A simplified downstream strategy combining sequential selective adsorption with solvent evaporation enabled purification of 5-HMF to 99% purity without complex extraction or biphasic separation steps. Compared with related systems, superior production and purification performance was observed. By combining green catalysis, continuous microreactor processing, direct syrup utilization, and simplified downstream purification, the proposed strategy offers a promising pathway to pharmaceutical-grade 5-HMF production, with reduced separation complexity and enhanced process intensification.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.